Clinical trial NCT01987102: Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.
Official title: An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Osteosarcoma
Keywords: Methotrexate
Rescue treatment
Lead sponsor: Isofol Medical AB
Sponsor class: INDUSTRY
First posted: 2013-11-19
Enrollment: 18
Sex: ALL
Minimum age (years): 6
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: An open-label, multicenter, phase I/II clinical trial to identify the \[6R\] 5,10-methylenetetrahydrofolate (arfolitixorin) dose with most favorable safety prospect and confirmed ability to mitigate high-dose methotrexate induced toxicity during treatment of osteosarcoma patients

Detailed description: This is a non-blinded, multicenter, exploratory study in osteosarcoma patients. The study focuses on the overall safety of the HDMTX courses given within a Methotrexate, Adriamycin (doxorubin) and cisPlatin (MAP) treatment schedule, which is closely related to the efficacy of the concomitantly administered folate rescue treatment. Additionally the study aimes to collect pharmacokinetic (PK) profiles of metotrexate (MTX) in serum, of folate metabolites in plasma and to decide the Modufolin® dose to use in future studies.

Patients are enrolled in the study at the first, third or the fifth HDMTX course in a MAP treatment schedule and receive folate rescue therapy according to a strategy based on the Children's Oncology Group (COG) treatment management recommendations used in study protocol AOST0331.

Folate rescue treatment with Calcium Folinate (SOC) or Modufolin® (MOD) commence 24 h after start of HDMTX administration and then every 6 h until the serum MTX levels are ≤0.1 μmol/L. In case delayed MTX elimination occurs with significant increase in S-creatinine and/or occurrence of oral mucositis or signs of hypo cellular bone marrow, the folate rescue dose and/or the administered hydration will be adjusted in accordance with the COG based MTX toxicity management recommendations.

All patients receives SOC (15 mg/m2) in the first 2 HDMTX courses and MOD in the following 2 courses. Patients are enrolled in one of two MOD dose cohorts: Cohort 1 (15 mg/m2) and Cohort 2 (30 or 7.5 mg/m2 depending on outcome of Cohort 1). Only patients with successful advancements from the first 2 HDMTX courses with Calcium Folinate are allowed to continue with MOD as rescue in the following MAP cycle.

Safety data will be reviewed by an independent board, Data and Safety Monitoring Board (DSMB) that will assess each patient and made recommendations regarding the enrolment of subsequent patients. Furthermore, the DSMB will make a dose level recommendation for Cohort 2 and also a recommendation whether younger children may be allowed in this cohort.

Eligibility criteria: Main Inclusion Criteria (HDMTX with SOC rescue):

* Patients must have histological evidence of osteosarcoma (metastatic disease accepted).
* Patients must be eligible for HDMTX according to the MAP treatment schedule described in the study protocol and fulfill all of the criteria below prior to first course of HDMTX in the study.

  1. Serum MTX: ≤0.1μmol/L
  2. Neutrophils: ≥0.25x109/L
  3. Platelets: ≥50x109/L
  4. Serum bilirubin: ≤1.25x upper limit of normal (ULN)
  5. Glomerular filtration rate (GFR) ≥70 mL/min/1.73m2
  6. No adverse event (AE) Grade 2 or more (NCI CTCAE v4.0) related to HDMTX hindering a potential HDMTX administration, at the discretion of the investigator.
* Patients must be 12-40 years of age. This age range may be extended with younger patients for enrolment in Cohort 2 if collected data from Cohort 1 support this and it is recommended by the DSMB.

Exclusion criteria for enrolment:

* Involvement in another clinical trial within 30 days before enrolment in the study.
* Hypersensitivity to Calcium Folinate.
* Previous treatment with glucarpidase.
* Known serious concomitant systemic disorders (e.g., active infection including HIV, liver dysfunction, cardiac disease) that, in the opinion of the investigator, would compromise the patient's ability to complete the study

Main Inclusion criteria for continuation (HDMTX treatment with Modufolin rescue):

* Patients, who were included in the study in accordance with the inclusion criteria above, must have received 2 adjacent courses of HDMTX with SOC rescue according to the MAP treatment schedule in accordance with this study protocol.
* Patients eligible for continued HDMTX according to the MAP treatment schedule and with a history of successful advancement from first to second HDMTX course within the previous MAP cycle
* Patients eligible for continued HDMTX according to the MAP treatment schedule and with a history of successful advancement to next MAP cycle after end of previous MAP cycle
* No significant changes to the patient's medical condition from the start of the study that in the opinion of the investigator would compromise the patient's ability to complete the study.
* Patients who have undergone surgical resection of their tumor must have recovered from their surgery and be eligible to continue on the MAP regimen; any post-operative complications should be resolved to NCI CTCAE v4.0 Grade 1 or better.

Primary outcomes:
measure: Number of AEs Per Severity (All Courses)
timeFrame: From the start of HDMTX administration through 8 days post dose for each course of HDMTX in total
measure: Number of HDMTX Related AEs Per Severity (All Courses)
timeFrame: From the start of HDMTX administration through 8 days post dose for each course of HDMTX in total
measure: Number of Ongoing AEs Per HDMTX Course
timeFrame: From the start of HDMTX administration through 8 days post dose for each course of HDMTX
measure: Number of Ongoing HDMTX Related AEs Per HDMTX Course
timeFrame: From the start of HDMTX administration through 8 days post dose for each course of HDMTX
Secondary outcomes:
measure: Number of Administered HDMTX Courses Classified as Having Met the Criteria for Successful Advancement According to Definition A and/or Definition B
timeFrame: 8 days after start of first and/or second HDMTX course in a MAP cycle
measure: Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement From First to Second HDMTX Course Within the Same MAP Cycle According to Definition A.
timeFrame: 8 days after start of first HDMTX course in a MAP cycle
measure: Number of Administered MAP Cycles Classified as Having Met the Criteria for Successful Advancement to Next MAP Cycle According to Definition B.
timeFrame: 8 days after start of second HDMTX course in a MAP cycle
measure: Time to Successful MTX Elimination (Definition C)
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Number of HDMTX Courses in Which the Initial Hydration Was Increased
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Number of HDMTX Courses With Delayed MTX Elimination (Definition D).
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Number of HDMTX Courses With Delayed Early MTX Elimination (Definition E).
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Number of HDMTX Courses With Delayed Late MTX Elimination (Definition F).
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Number of Grade A1, Grade A2, Grade B, Grade C, or Grade D Excretion Toxicities as Listed in the MTX-toxicity Management Instructions
timeFrame: Time from start of MTX treatment until serum MTX level is ≤ 0.1 μmol/L
measure: Characterization (Number/Severity) of All Reported AEs During the ENTIRE STUDY PERIOD.
timeFrame: From the start of HDMTX administration through 8 days post dose for all 4 courses of HDMTX in total
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: Fakultní nemocnice Brno Klinika detske onkologie
city: Prague
country: Czechia
facility: Fakultní nemocnice v Motole
city: Budapest
country: Hungary
facility: Semmelweis Egyetem II. Sz. Gyermekgyógyászati Klinika
city: Warszawa
country: Poland
facility: Instytut Matki i Dziecka
city: Lund
country: Sweden
facility: Department of Oncology, Skåne University Hospital
Study officials:
affiliation: Department of Oncology, Skåne University Hospital
name: Mikael Eriksson, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: